INTEGRATED SURGICAL SYSTEMS !! - 500 Beiträge pro Seite

[MorningGlory]

Nehmt diese Aktie (Nasdaq) die laufende Woche `mal auf Eure Watchlist. Kurspotential + 300 % !!

[TheChemist]

300% Chance?
Möglich, aber der Kurs ist leider nicht grundlos so stark zurückgekommen. Meines Wissens ist es ISS nicht gelungen, eine US-Zulassung für ROBODOC zu bekommen. In Europa waren sie zwar die ersten im Markt, wurden inzwischen aber von Ortho-Maquet ("CASPAR") überholt. Wer wirklich einsteigen will, sollte mal den letzten Quartalsbericht lesen (s. u.)
Gruß
TheChemist



May 15, 2000

INTEGRATED SURGICAL SYSTEMS INC (RDOC)
Quarterly Report (SEC form 10QSB)
MANAGEMENT`S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
Results of Operations

Three Months Ended March 31, 2000 Compared to Three Months Ended March 31, 1999

Net Sales. Net sales for the three months ended March 31, 2000 (the "2000 Interim Period") were approximately $730,000, largely attributable to revenues recognized from the sale of implant software libraries and service contracts compared to the three months ended March 31, 1999 (the "1999 Interim Period") of approximately $2,287,000, which included the sale of three ROBODOC systems.

Cost of Sales. Cost of sales for the 2000 Interim Period was approximately $342,000 (47% of net sales) as compared to the 1999 Interim Period of approximately $1,105,000 (48% of net sales).

Selling, General and Administrative. Selling, general and administrative expenses for the 2000 Interim Period (approximately $1,112,000) decreased by approximately $465,000, or 29.5% as compared to the 1999 Interim Period (approximately $1,577,000). Marketing costs decreased approximately $353,000 due to a reduction in the number of field sales employees. General and administrative costs decreased approximately $112,000 also as a result of lower staffing levels.

Research and Development. Research and development expenses for the 2000 Interim Period (approximately $1,747,000) increased by approximately $117,000, or approximately 7%, as compared to the 1999 Interim Period (approximately $1,630,000), due to additional engineering staff required to support the successful knee replacement application and the additional travel and expenses associated with this project.

Interest Income. Interest income for the 2000 Interim Period (approximately $20,000) decreased by approximately $17,000, or 46%, as compared to the 1999 Interim Period (approximately $37,000), primarily due to lower average cash balances during the 2000 Interim Period as a result of the Company`s 1999 operating loss.

Other Income and Expense. Other expense for the 2000 Interim Period was approximately $176,000 compared to expense of approximately $288,000 in the 1999 Interim Period. The decrease in expense ($119,000) is primarily attributable to a decrease in foreign currency transaction losses in the 2000 Interim Period versus those recognized in the 1999 Interim Period.

Net Loss. The net loss for the 2000 Interim Period (approximately $2,640,000) increased by approximately $334,000, , as compared to the net loss for the 1999 Interim Period (approximately $2,306 ,000). The increased loss was a result of lower revenues.






Liquidity and Capital Resources

Since inception, the Company`s expenses have exceeded net sales. Operations have been funded primarily from the issuance of debt and the sale of equity securities aggregating approximately $47.2 million. In addition, the Company was the beneficiary of proceeds from a $3 million key-man life insurance policy in 1993 upon the death of one of its executives.

The report of the independent auditors on the Company`s December 31, 2999 financial statements included an explanatory paragraph indicating there is substantial doubt of the Company`s ability to continue as a going concern.

The Company`s use of cash in operating activities of approximately $2,718,000 in the 2000 Interim Period increased by approximately $2,646,000 as compared to cash usage due to operating activities in the 1999 Interim Period of approximately $72,000. The increase in operating cash usage in the 2000 Interim Period was primarily a result of operating losses, an increase in inventory of approximately 613,000, a decrease in accounts payable of approximately $263,000, and an increase in accounts receivable of approximately $282,000. The Company believes that it has developed a viable plan to address these issues and that its plan will enable the Company to continue as a going concern through the end of 2000. This plan includes the expansion of the geographic markets in which its products are sold, new applications for its products, the consummation of equity financings in amounts sufficient to fund further growth, to attain its product development and marketing objectives and meet its working capital demands, and the reduction of certain operating expenses as necessary. Although the Company believes that its plan will be realized, there is no assurance that these events will occur. The financial statements do not include any adjustments to reflect the uncertainties related to the recoverability and classification of assets or the amounts and classification of liabilities that may result from the inability of the Company to continue as a going concern.

The Company`s cash flow from investing activities, improved by approximately 604,000. The improvement in operating cash usage in the interim period was primarily due to a decrease in investments in sales type leases and in property and equipment.

Cash provided by financing activities in the 2000 Interim Period was approximately $705,000 and decreased by approximately $931,000 as compared to the financing activities during the 1999 Interim Period. In February 2000 the Company received net proceeds of approximately $1,880,000 from the sale of Series F Preferred Stock and Warrants (see Note C to the financial statements and Part II, Item 2. Changes in Securities and Use of Proceeds) and retired the outstanding Series E Convertible Preferred Stock in the amount of $1,185,000.

The Company`s available cash resources, together with anticipated cash flows from operations, may not be sufficient to continue operations without additional financing. The Company has been able to raise capital from the investment community under terms that have been satisfactory. The Company continues to seek additional financing, such financing may not be available on terms acceptable to the Company. The Company is attempting to reduce operating expense to a point where funds generated internally will mitigate the possibility of having to look to the investment community for capital.

[Doc Invest]

hab ich heute gefunden:

Integrated Surgical Systems Announces First Successful U.S. Surgery With NeuroMate(TM) System for Parkinson`s Disease Patient Performed at U.S.C.

DAVIS, Calif., June 9 /PRNewswire/ -- Integrated Surgical Systems, Inc. (Nasdaq: RDOC; Easdaq) (ISS), a pioneer in medical robotics and the world leader in image-directed, robotic products for surgical applications in the fields of neurological and orthopedic surgeries, today announced that it performed the first successful U.S. surgery with its NeuroMate(TM) System to treat a Parkinson`s Disease patient.

Commenting on the surgery, Dr. Michael Dogali, Co-Director of the Movement Disorder Program and Professor of Neurosurgery at the University of Southern California Medical Center stated, ``Implanting the Activa®, a deep brain stimulator, with the NeuroMate(TM) System was much easier and more efficient than with traditional stereotactic surgical methods. This is our first surgery with the NeuroMate(TM) System utilizing single tract microelectrode recording. We believe that we can further improve the method as we employ simultaneous multiple microelectrodes and as we further develop the full capability of the system.

The NeuroMate(TM) System we employed is similar to that developed and used by Professor Alim-Luis Benabid of Grenoble, France over the past several years.``

Dr. Dogali is actively employing and developing the NeuroMate(TM) System for use in Parkinson`s Disease and other stereotactic operations. ``We are very pleased to have reached this major milestone for the U.S. Market,`` said Dr. Ramesh Trivedi, President and CEO for ISS.

``The NeuroMate(TM) System developed and used by Prof. Alim-Louis Benabid of Grenoble, France, has been used in France for some time. This is the first time the NeuroMate(TM) System was used for implanting the Activa®, a deep brain stimulator, in the U.S.A. As we become more experienced in this particular application, we believe that use of the NeuroMate(TM) System will become the standard tool to accurately implant stimulators such as those used in the treatment of Parkinson`s Disease patients.By some accounts, there are over 1 million patients in the U.S. alone, who could benefit from such treatment.``

A NeuroMate(TM) System is also used at Wayne State University by Dr. Lucia Zamorano for tumor biopsies and resection. Further development work is ongoing at Dr. Zamorano`s laboratories.

NOTE: Activa® is a registered trademark of Medtronics, Inc..

The Products: The ISS neurosurgery product, NeuroMate®, is the first robotic technology for use in stereotactic brain surgery. NeuroMate® consists of a robotic arm assembly and a PC-based positioning system. The product interfaces with the VoXim Surgical Planning System from ISS, as well as other popular third-party planning stations. ISS has installed 16 NeuroMate® systems in the U.S., Europe, Middle East, and Japan. ROBODOC® is the ISS robotic surgery product used for total hip arthroplasty. ROBODOC® consists of a robotic arm assembly and a PC-based positioning system. The product interfaces with the Orthodoc® Surgical Planning System from ISS. ISS has installed 37 ROBODOC® systems worldwide.

The Company: Integrated Surgical Systems, Inc. develops, manufactures, markets and services computer-controlled, image-directed robotic products for surgical applications. ISS produces the ROBODOC® Surgical Assistant System (ROBODOC), which is designed for orthopedic applications. The ROBODOC System has been used to perform precise total hip replacement surgeries on more than 6,000 patients worldwide. ROBODOC is currently being marketed in Europe and the Middle East. NeuroMate(TM), ISS` neurosurgery product, is the first robotic technology for use in stereotactic brain surgery and has supported neurosurgical procedures on more than 2,000 patients to date.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including the timely development and market acceptance of new products and upgrades to existing products, the impact of competitive products and pricing, and other risks detailed from time to time in the company`s filings with the Securities and Exchange Commission (SEC).

NOTE: ROBODOC® is a registered trademark of Integrated Surgical Systems, Inc. NeuroMate(TM) is a trademark of Innovative Medical Machines International, S.A.